In the BioHarmony Drug Report Database
Daptomycin
Cubicin, Cubicin Rf, Daptomycin (daptomycin) is a protein pharmaceutical. Daptomycin was first approved as Cubicin on 2003-09-12. It is used to treat bacteremia, bacterial infections, and bacterial skin diseases in the USA. It has been approved in Europe to treat bacteremia, bacterial endocarditis, bacterial skin diseases, gram-positive bacterial infections, and soft tissue infections. Cubicin’s patents are valid until 2033-09-11 (FDA).
Trade Name
|
Cubicin |
|---|---|
Common Name
|
daptomycin |
ChEMBL ID
|
CHEMBL387675 |
Indication
|
bacteremia, bacterial endocarditis, bacterial infections, bacterial skin diseases, gram-positive bacterial infections, soft tissue infections |
Drug Class
|
Aptamers, classical and mirror; antibiotics (Streptomyces strains) |
Image (chem structure or protein)